Estimating influenza vaccine effectiveness using routine surveillance data among children aged 6-59 months for five consecutive influenza seasons

被引:16
|
作者
Su, Wei-Ju [1 ,2 ,3 ]
Chan, Ta-Chien [4 ]
Chuang, Pei-Hung [5 ]
Liu, Yu-Lun [1 ]
Lee, Ping-Ing [3 ]
Liu, Ming-Tsan [1 ]
Chuang, Jen-Hsiang [1 ,6 ]
机构
[1] Minist Hlth & Welf, Ctr Dis Control, Taipei 10050, Taiwan
[2] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan
[4] Acad Sinica, Res Ctr Humanities & Social Sci, Taipei 115, Taiwan
[5] Taiwan Fdn Poison Control, Taipei, Taiwan
[6] Natl Yang Ming Univ, Inst Hlth Care Adm, Taipei 112, Taiwan
关键词
Influenza vaccine effectiveness; Case-control studies; Influenza surveillance; LABORATORY-CONFIRMED INFLUENZA; IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; HEALTHY-CHILDREN; ADVISORY-COMMITTEE; TRIVALENT; EFFICACY; VIRUS; HOSPITALIZATIONS; RECOMMENDATIONS;
D O I
10.1016/j.ijid.2014.11.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We aimed to estimate the pooled vaccine effectiveness (VE) in children over five winters through data linkage of two existing surveillance systems. Methods: Five test-negative case-control studies were conducted from November to February during the 2004/2005 to 2008/2009 seasons. Sentinel physicians from the Viral Surveillance Network enrolled children aged 6-59 months with influenza-like illness to collect throat swabs. Through linking with a nationwide vaccination registry, we measured the VE with a logistic regression model adjusting for age, gender, and week of symptom onset. Both fixed-effects and random-effects models were used in the meta-analysis. Results: Four thousand four hundred and ninety-four subjects were included. The proportion of influenza test-positive subjects across the five seasons was 11.5% (132/1151), 7.2% (41/572), 23.9% (189/791), 6.6% (75/1135), and 11.2% (95/845), respectively. The pooled VE was 62% (95% confidence interval (CI) 48-83%) in both meta-analysis models. By age category, VE was 51% (95% CI 23-68%) for those aged 6-23 months and 75% (95% CI 60-84%) for those aged 24-59 months. Conclusions: Influenza vaccination provided measurable protection against laboratory-confirmed influenza among children aged 6-59 months despite variations in the vaccine match during the 2004/2005 to 2008/2009 influenza seasons in Taiwan. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 50 条
  • [31] Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013 The Importance of Two Priming Doses
    Thompson, Mark G.
    Clippard, Jessie
    Petrie, Joshua G.
    Jackson, Michael L.
    McLean, Huong Q.
    Gaglani, Manjusha
    Reis, Evelyn C.
    Flannery, Brendan
    Monto, Arnold S.
    Jackson, Lisa
    Belongia, Edward A.
    Murthy, Kempapura
    Zimmerman, Richard K.
    Thaker, Swathi
    Fry, Alicia M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (03) : 299 - 308
  • [32] Influenza Vaccine Effectiveness Estimates among US Department of Defense Adult Beneficiaries over Four Consecutive Influenza Seasons: A Test-Negative Design Study with Different Control Groups
    Hu, Wenping
    Sjoberg, Paul A.
    DeMarcus, Laurie S.
    Robbins, Anthony S.
    VACCINES, 2022, 10 (01)
  • [33] Coverage and parental perceptions of influenza vaccination among parents of children aged 6 to 23 months in Hong Kong
    Lau, Joseph T. F.
    Mo, Phoenix K. H.
    Cai, Yan Shan
    Tsui, Hi Yi
    Choi, Kai Chow
    BMC PUBLIC HEALTH, 2013, 13
  • [34] Trends in compliance with two-dose influenza vaccine recommendations in children aged 6 months through 8 years, 2010-2015
    Lin, Xia
    Fiebelkorn, Amy Parker
    Pabst, Laura J.
    VACCINE, 2016, 34 (46) : 5623 - 5628
  • [35] Influenza vaccination encouraged for all children aged 6-23 months in the United States: vaccine supply and feasibility implications
    Iwane, MK
    Bridges, CB
    Singleton, JA
    Szilagyi, PG
    OPTIONS FOR THE CONTROL OF INFLUENZA V, 2004, 1263 : 644 - 648
  • [36] Estimating vaccine effectiveness against severe influenza in England and Scotland 2011/2012: applying the screening method to data from intensive care surveillance systems
    Thomas, H. L.
    Andrews, N.
    Green, H. K.
    Boddington, N. L.
    Zhao, H.
    Reynolds, A.
    McMenamin, J.
    Pebody, R. G.
    EPIDEMIOLOGY AND INFECTION, 2014, 142 (01) : 126 - 133
  • [37] A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa
    Cohen, Cheryl
    du Plessis, Mignon
    Martinson, Neil
    Moyes, Jocelyn
    Walaza, Sibongile
    Wolter, Nicole
    Makhasi, Mvuyo
    Moosa, Fahima
    Charles, Myrna
    Samuels, Aaron M.
    Tempia, Stefano
    Moloantoa, Tumelo
    Ncwana, Bekiwe
    Phalatse, Louisa
    Buys, Amelia
    Fry, Alicia
    Baumgartner, Eduardo Azziz
    von Gottberg, Anne
    Kleynhans, Jackie
    JOURNAL OF INFECTIOUS DISEASES, 2024, : e328 - e336
  • [38] The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24-59 months in The Gambia: a phase 4, open label randomised, controlled trial
    Peno, Chikondi
    Armitage, Edwin P.
    Clerc, Melanie
    Lopez, Carlos Balcazar
    Jagne, Ya Jankey
    Drammeh, Sainabou
    Jarju, Sheikh
    Sallah, Hadijatou
    Senghore, Elina
    Lindsey, Benjamin B.
    Camara, Janko
    Bah, Sulayman
    Mohammed, Nuredin, I
    Dockrell, David H.
    Kampmann, Beate
    Clarke, Ed
    Bogaert, Debby
    de Silva, Thushan, I
    LANCET MICROBE, 2021, 2 (12): : E656 - E665
  • [39] Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study
    Esposito, Susanna
    Nauta, Jos
    Lapini, Giulia
    Montomoli, Emanuele
    van de Witte, Serge
    VACCINE, 2022, 40 (18) : 2626 - 2634
  • [40] A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months
    Esposito, Susanna
    Marchisio, Paola
    Ansaldi, Filippo
    Bianchini, Sonia
    Pacei, Michela
    Baggi, Elena
    Trabattoni, Dania
    Icardi, Giancarlo
    Principi, Nicola
    VACCINE, 2010, 28 (38) : 6137 - 6144